Naratriptan Usv

Naratriptan, the active ingredient in Naratriptan Usv, is a selective serotonin (5-HT1) receptor agonist presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Naratriptan Usv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class and is used to treat migraine by acting on serotonergic pathways.

Migraine: aborts acute migraine attacks and relieves headache pain. Migraine with aura: provides rapid relief of headache and associated visual disturbances. Migraine without aura: reduces the severity and duration of headache episodes.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Nausea: transient upset stomach. - Dry mouth: reduced salivation. - Fatigue: feeling of tiredness. - Tingling sensation: paresthesia in extremities.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and muscle rigidity. - Cardiac ischemia: chest discomfort due to reduced coronary blood flow. - Severe hypertension: sudden increase in blood pressure. - Allergic reaction: rash, swelling, or anaphylaxis. - Stroke: neurological deficits requiring urgent care.

Before prescribing Naratriptan, clinicians should consider the following precautions.

Cardiovascular assessment: evaluate history of coronary artery disease, angina, or uncontrolled hypertension. Medication review: avoid use with other serotonergic agents that may increase serotonin syndrome risk. Pregnancy counseling: discuss unknown safety profile and weigh benefits against potential risks. Elderly monitoring: start at the lowest effective dose and monitor for adverse reactions. Drug‑specific contraindications: do not use in patients with known hypersensitivity to naratriptan. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Other triptans or ergot alkaloids: additive vasoconstrictive effects. - SSRIs, SNRIs, or other serotonergic agents: heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance antihypertensive effect. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase naratriptan plasma levels. - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce efficacy.